Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sumatriptan
Drug ID BADD_D02098
Description Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches.[L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.[A179761] Sumatriptan was granted FDA approval on 28 December 1992.[L6805]
Indications and Usage A combination sumatriptan and [naproxen] tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.[L6793] Sumatriptan nasal powder, nasal spray, subcutaneous injection, and tablets are indicated to treat migraines with or without auras in adults.[L6796,L6799,L6805,L6808,L6811] One of the subcutaneous formulations of sumatriptan is also indicated to treat cluster headaches in adults[L6805], while the other subcutaneous formulation is not.[L6808]
Marketing Status approved; investigational
ATC Code N02CC01
DrugBank ID DB00669
KEGG ID D00451
MeSH ID D018170
PubChem ID 5358
TTD Drug ID D0Z6UC
NDC Product Code 80425-0258; 52932-0733; 42043-220; 65145-118; 72189-404; 62331-048; 42043-222; 55150-173; 55700-969; 63629-8701; 0173-0737; 55700-918; 70069-804; 0527-1859; 63304-097; 69452-344; 0480-2014; 45802-619; 0173-0736; 0245-0812; 60429-995; 63304-098; 63304-099; 53873-058; 67835-5011; 0173-0479; 0173-0524; 66993-084; 0527-1818; 36000-289; 66993-082; 69452-345; 69452-346; 71921-170; 58437-017; 0143-9638; 0173-0523; 63187-164; 63187-323; 63629-8703; 69097-644; 80425-0318; 50370-0029; 53873-057; 58437-016; 58437-018; 0173-0735; 53002-3562; 66993-083; 80425-0224; 53873-059; 42043-221; 0173-0478; 66993-081; 68071-2825; 0480-2013; 45802-598; 0173-0739
UNII 8R78F6L9VO
Synonyms Sumatriptan | 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide | Sumatriptan Succinate | Succinate, Sumatriptan | GR-43175 | GR 43175 | GR43175 | Imigran
Chemical Information
Molecular Formula C14H21N3O2S
CAS Registry Number 103628-46-2
SMILES CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angiopathy24.03.02.007--Not Available
Drug resistance08.06.01.0050.000056%Not Available
Induration08.01.03.020--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Electrocardiogram change13.14.05.014--Not Available
Infarction24.04.02.017--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Limb discomfort15.03.04.014--Not Available
Ischaemia24.04.02.004--Not Available
Jaw disorder15.02.04.009--Not Available
Mediastinal disorder22.09.03.001--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Poisoning12.03.01.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Feeling of body temperature change08.01.09.012--Not Available
Scleral disorder06.09.06.002--
Ill-defined disorder08.01.03.0490.000150%Not Available
Intervertebral disc disorder15.10.01.003--Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.000189%Not Available
Nasal disorder22.04.03.004--Not Available
Lipohypertrophy23.07.01.005; 14.08.04.009--
Urethritis noninfective20.07.02.002--Not Available
Cystitis noninfective20.03.02.001--
Application site discomfort12.07.01.034; 08.02.01.034--Not Available
Lichenoid keratosis23.01.01.004--Not Available
Right ventricle outflow tract obstruction02.08.01.004; 24.03.03.016; 03.07.10.002--Not Available
Nephritic syndrome20.05.01.0060.000083%Not Available
The 14th Page    First    Pre   14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene